Ethos Cannabis Launches New Huny Edibles Exclusive to Pennsylvania Stores
Backed by research collaboration with Thomas Jefferson University, wellness-based pectin-based edibles featuring unique cannabinoid blends available now
PHILADELPHIA, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Ethos Cannabis, a leading multistate operator with a presence in Massachusetts, Ohio, and Pennsylvania, announces the launch of Huny Ratio Troches, a new line of pectin-based edibles exclusively available at Ethos dispensaries across Pennsylvania beginning today. This product is the first to be developed as part of Ethos' research collaboration with the Sidney Kimmel Medical College at Thomas Jefferson University.
These fruit-forward troches offer a convenient, enjoyable way to incorporate cannabis into daily wellness routines. Since 2020, Ethos has collaborated with Thomas Jefferson University under a formal Research Agreement to study ways to improve health outcomes for medical marijuana patients. The carefully crafted cannabinoid blends reflect Ethos' commitment to education, wellness, and the philosophy that 'Better is Better.'
The Huny Ratio Troches, selling for $30 or less, are available in three distinct flavors and cannabinoid blends, each crafted with real fruit juice:
Berry Blend – 1THC:1CBN Troches
Citrus – 1THC:30CBD Troches
Strawberry Lemon – 1THC:1CBD Troches
'This product launch marks a strategic expansion of the Huny product portfolio, reinforcing our goal to provide innovative cannabis solutions tailored to consumer needs,' said Gibran Washington, CEO of Ethos Cannabis. 'Developed in collaboration with Thomas Jefferson University, these troches reflect our commitment to advancing cannabis education and wellness. At Ethos, we know life moves fast, and wellness should keep up. The Ratio Troches offer a delicious and practical way to incorporate cannabis into daily routines—whether it's to power through a busy day or unwind in the evening.'
By launching the Huny Ratio Troches exclusively in Pennsylvania, Ethos is bringing cutting-edge, research-backed cannabis solutions directly to patients who can benefit from them the most. This aligns with the company's mission to enhance wellness through science and education, reinforcing its leadership in the state's medical marijuana industry.
"Medical cannabis has transformed how we manage symptoms and improve quality of life for patients, but there's still so much to learn," said Dr. Brooke Worster, Associate Professor at Thomas Jefferson University and clinical researcher in Jefferson's medical cannabis research program. "Through our partnership with Ethos, we're advancing real-world research on how different cannabis formulations impact patients. The introduction of these troches gives us another opportunity to explore precise dosing and alternative delivery methods that could make cannabis more accessible and effective for those who need it."
Ethos' Pennsylvania locations will be running a 25% off promotion of the new product on February 8th and 9th. For more information or to find an Ethos location near you, visit www.ethoscannabis.com.
About Ethos CannabisEthos Cannabis is a multi-state operator with operations in Pennsylvania, Massachusetts, and Ohio. Ethos also boasts four brands in its portfolio, Natural Selections (MA & PA), Eleven (MA & PA), Headliners (MA), and Meigs County (OH). Ethos is a leading vertically integrated, retail-focused platform in the Mid-Atlantic, East Coast, and Midwest markets of the U.S. This platform serves mainstream consumers while expanding the health and wellness market through relationships with Thomas Jefferson University and other academic medical institutions and strategic partnerships. Ethos is dedicated to helping individuals feel and live better through their experiences with cannabis. For more information on Ethos, visit ethoscannabis.com.
Media Contact: ethos@kcsa.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
20-05-2025
- Buzz Feed
Signs Of Healthy Poop: What Doctors Want You To Know
Everyone poops, but it's still something a lot of us have an awfully hard time talking about. (Unless you're my 6-year-old and 3-year-old, who cannot talk about poop enough, it turns out.) But it's unfortunate that poop talk tends to make adults squeamish, because our stool can offer some powerful clues about what's going on inside our guts — and even more broadly within our bodies. And doctors really do wish people would lean into it. 'When I ask patients to describe their stool, even when they're at the GI doctor, you can almost immediately sense their discomfort,' Christopher Henry, a gastroenterologist at Thomas Jefferson University in Philadelphia, told HuffPost. Enter the Bristol Stool Chart (sometimes called the Bristol Stool Form Scale or the Meyers Scale), a diagnostic tool that health professionals can use with their patients to help determine what's normal (and what's not) in terms of size, texture and color of poop. In general, ideal poop is Type 3 or Type 4. Type 1 or Type 2, on the other hand, can indicate a person is struggling with constipation. And Types 5, 6 or 7 can suggest diarrhea — though not always. 'Sometimes I'll have patients with very severe constipation, and they'll have periodic diarrhea,' Henry said. That particular example shows why the stool chart really shouldn't be used by laypeople to self-diagnose. Instead, people should see it as a jumping-off point for health-related conversations — and it certainly can help make those discussions less awkward. Many people find it easier to point to a line on a chart than to have to search for the words to describe their stool to a provider, Henry said. Doctors, on the other hand, can use the chart to help diagnose conditions like various types of irritable bowel syndrome, or IBS. If your poop pretty consistently falls outside of the normal types on the chart, that's definitely worth flagging to your primary care physician, who might refer you to a specialist. Significant changes in poop frequency or form also are worth noting. And don't ignore other gastrointestinal symptoms. That includes heartburn that doesn't get resolved with antacids, blood in your stool, severe pain or unintentional weight loss. Even if your poop-related issues turn out to be relatively mild, a doctor might be able to help you with some simple changes that can help you achieve the ideal poop (and feel better overall) — like getting sufficient fiber and water. But experts caution against getting too caught up on whether your poop is exactly the right texture and color based on the chart ― especially because there are many slightly different iterations of it floating around the web. Also, people's stool color can vary based on what they eat. But what the Bristol Stool Chart can do pretty well is provide clarity. Henry recalled an experience when he was working with multiple patients complaining of diarrhea, but when he asked them to point to what their stool looked like on the chart, they pointed to Type 1 — which actually indicates constipation. They believed that diarrhea referred more to frequency, rather than to a particular stool form. In cases like that, the chart helps to create a shared language, to make sure patients and their providers are on the same page. 'I think of it kind of like a Rosetta stone. To make sure we're using the same words to mean the same things,' Henry said. 'It's a platform for patients and doctors to have better conversations.' Because talking about poop may not be most grown-ups' favorite thing to do, but it's an important part of overall well-being. HuffPost.
Yahoo
12-02-2025
- Yahoo
Advanced cancer treatment coming to Greeneville Community Hospital thanks to $1M from Niswonger family
GREENEVILLE, Tenn. (WJHL) — A $1 million donation from Scott Niswonger and his family will bring an advanced cancer treatment center and new technology to the Greeneville Community Hospital. Ballad Health announced that it will name the upcoming center the Niswonger Family Radiation Treatment Center in honor of the donors. The investment will help facilitate a TrueBeam linear accelerator and Ethos adaptive radiotherapy system to enhance radiation treatments, according to Ballad. Scott Niswonger told News Channel 11 on Tuesday during a donation ceremony that the new technology will bring high-tech treatment to the region, keeping families from having to travel out of the Tri-Cities. 'Well, it's been a great day. We have the oldest linear accelerator in the Ballad system. And it dawned on me, you know, we spent a lot of time on educating children in programs K through 12. But if a child isn't well, is unhealthy or an adult, they're not going to have the opportunities that others have. And so hopefully by having this piece of equipment here in Greenville, folks won't have to drive to Vanderbilt.' 'This is a monumental step forward for Greeneville Community Hospital,' said the hospital's CEO, Eric Carroll. 'Thanks to the Niswonger family, we can continue offering leading-edge cancer treatments close to home. Their generosity ensures that patients in Greene County and beyond receive the highest level of care.' Dr. John Boys is the hospital's radiation oncologist and will lead the ship at the new center. 'This contribution will allow us to expand our capabilities and offer even more precise and effective treatments for our patients,' Dr. Boys said. 'Having access to the latest radiation therapy technology means our community members won't have to travel far for exceptional care. I'm deeply grateful to Scott and Nikki for their generosity and commitment to Greeneville. TrueBeam and Ethos allow faster treatment, better targeting and more precise access and tracking — all supporting better outcomes for our patients.' The donation comes around two months after Ballad Health announced a major expansion of its cancer care in Johnson City, which includes additional exam rooms, physician offices and two chemotherapy wings with private rooms. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
07-02-2025
- Yahoo
Ethos Cannabis Launches New Huny Edibles Exclusive to Pennsylvania Stores
Backed by research collaboration with Thomas Jefferson University, wellness-based pectin-based edibles featuring unique cannabinoid blends available now PHILADELPHIA, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Ethos Cannabis, a leading multistate operator with a presence in Massachusetts, Ohio, and Pennsylvania, announces the launch of Huny Ratio Troches, a new line of pectin-based edibles exclusively available at Ethos dispensaries across Pennsylvania beginning today. This product is the first to be developed as part of Ethos' research collaboration with the Sidney Kimmel Medical College at Thomas Jefferson University. These fruit-forward troches offer a convenient, enjoyable way to incorporate cannabis into daily wellness routines. Since 2020, Ethos has collaborated with Thomas Jefferson University under a formal Research Agreement to study ways to improve health outcomes for medical marijuana patients. The carefully crafted cannabinoid blends reflect Ethos' commitment to education, wellness, and the philosophy that 'Better is Better.' The Huny Ratio Troches, selling for $30 or less, are available in three distinct flavors and cannabinoid blends, each crafted with real fruit juice: Berry Blend – 1THC:1CBN Troches Citrus – 1THC:30CBD Troches Strawberry Lemon – 1THC:1CBD Troches 'This product launch marks a strategic expansion of the Huny product portfolio, reinforcing our goal to provide innovative cannabis solutions tailored to consumer needs,' said Gibran Washington, CEO of Ethos Cannabis. 'Developed in collaboration with Thomas Jefferson University, these troches reflect our commitment to advancing cannabis education and wellness. At Ethos, we know life moves fast, and wellness should keep up. The Ratio Troches offer a delicious and practical way to incorporate cannabis into daily routines—whether it's to power through a busy day or unwind in the evening.' By launching the Huny Ratio Troches exclusively in Pennsylvania, Ethos is bringing cutting-edge, research-backed cannabis solutions directly to patients who can benefit from them the most. This aligns with the company's mission to enhance wellness through science and education, reinforcing its leadership in the state's medical marijuana industry. "Medical cannabis has transformed how we manage symptoms and improve quality of life for patients, but there's still so much to learn," said Dr. Brooke Worster, Associate Professor at Thomas Jefferson University and clinical researcher in Jefferson's medical cannabis research program. "Through our partnership with Ethos, we're advancing real-world research on how different cannabis formulations impact patients. The introduction of these troches gives us another opportunity to explore precise dosing and alternative delivery methods that could make cannabis more accessible and effective for those who need it." Ethos' Pennsylvania locations will be running a 25% off promotion of the new product on February 8th and 9th. For more information or to find an Ethos location near you, visit About Ethos CannabisEthos Cannabis is a multi-state operator with operations in Pennsylvania, Massachusetts, and Ohio. Ethos also boasts four brands in its portfolio, Natural Selections (MA & PA), Eleven (MA & PA), Headliners (MA), and Meigs County (OH). Ethos is a leading vertically integrated, retail-focused platform in the Mid-Atlantic, East Coast, and Midwest markets of the U.S. This platform serves mainstream consumers while expanding the health and wellness market through relationships with Thomas Jefferson University and other academic medical institutions and strategic partnerships. Ethos is dedicated to helping individuals feel and live better through their experiences with cannabis. For more information on Ethos, visit Media Contact: ethos@ in to access your portfolio
